Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3979344 | Bulletin du Cancer | 2011 | 8 Pages |
Abstract
Our results suggest that trastuzumab concurrently with WBRT may have a potential clinical impact with low toxicity. Although promising, these preliminary data warrant further validation of trastuzumab as radio sensitizer for WBRT in brain metastases from breast cancer in the setting of a clinical trial. Larger prospective studies are needed to confirm these results.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hind Riahi Idrissi, Cyrus Chargari, Marc A. Bollet, Romuald Le Scodan, Liliane Olivier, Thierry Dorval, Virginie Marchand, Paul Cottu, Véronique Dieras, François Campana, Alain Fourquet, Youlia M. Kirova,